Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Costs and expenses: | ||
| Cost of product sales | 4,606 | 4,409 |
| Research and development | 11,676 | 8,436 |
| Selling, general and administrative | 30,651 | 27,715 |
| Total costs and expenses | 46,933 | 40,560 |
| Income from operations | 11,885 | 12,773 |
| Interest income | 1,205 | 591 |
| Interest expense | (1,433) | (1,853) |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's SG&A?
- Rigel Pharmaceuticals (RIGL) reported SG&A of $30.65M in Q1 2026.
- How has Rigel Pharmaceuticals's SG&A changed year-over-year?
- Rigel Pharmaceuticals's SG&A increased by 10.6% year-over-year, from $27.72M to $30.65M.
- What is the long-term trend for Rigel Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's SG&A has grown at a 6.0% compound annual growth rate (CAGR), from $91.89M to $115.9M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Rigel Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude